Infertility. Female infertility of uterine origin
Conditions
Interventions
Intervention 1: Control group: pharmacotherapy group (C): Group C receives only the usual pharmacotherapy. Estrogen in the form of estradiol 2 mg tablets will start on the second day of the menstrual
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Age between 20-40 years Having at least two history of failed transfers Having 2 grade A or B embryo for transfers Having uterine artery resistance above 1.76
Exclusion criteria
Exclusion criteria: Having any of the cases of congenital anomaly of the uterus Having fibroids or any intrauterine lesions Having severe endometriosis Having uterine myomas Having uterine adenomyosis Having ovarian cysts and antral follicles larger than 12 mm in size having severe ovulation disorder including long-term oligoamenorrhea, premature ovarian failure, and hypothalamic amenorrhea Having any internal diseases related to blood flow disorders such as diabetes and dyslipidemia, anorexia, smoking and alcohol consumption. Having special diets such as vegetarianism Having autoimmune disease Having hypertension and coagulation disorders Having intrauterine adhesions (Asherman's syndrome) Having organic injuries Having uterine dysplasia Having mental illnesses Having mental disorders Having severe depression Having contraindications for estrogen therapy Having anemia Having hyperthyroidism Having heart disease Having liver disease Having kidney disease Having others diseases that lead to decreased menstruation. If the embryos are not Grade A or B after resuscitation, if the thickness of the endometrium is less than 6 mm on the day of transfer, or if they do not follow the prescribed treatment (such as a mistake in taking or omitting intervention or examination sessions) they are not included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigating the state of uterine blood supply (arterial resistance index, arterial pulse index, peak systolic velocity, end-diastolic velocity). Timepoint: before intervention (10th day of of menstruation), after intervention (10th day of of menstruation). Method of measurement: Transvaginal ultrasound.;Endometrial thickness. Timepoint: before intervention (10th day of of menstruation), after intervention (10th day of of menstruation). Method of measurement: Transvaginal ultrasound.;Successful pregnancy. Timepoint: 14 days after embryo transfer in cleavage stage and 12 days after embryo transfer in blastocyst stage. Method of measurement: Measuring serum BHCG level and checking the ratio of cases with a positive result (BHCG level = 25 [10]mIU/ml) to all transferred cases.;Implantation rate. Timepoint: Fifth week of pregnancy. Method of measurement: The ratio of the number of intrauterine gestational sacs observed by vaginal ultrasound in the fifth week of pregnancy divided by the number of embryos transferred.;Fetal growth. Timepoint: Up to the 12th week of pregnancy. Method of measurement: Ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Endometrial pattern. Timepoint: At the beginning of the intervention (day 10 of menstruation), at the end of the intervention (day 10 of menstruation). Method of measurement: Using transvaginal ultrasound.;Sexual performance index. Timepoint: At the beginning of the intervention (day 10 of menstruation), at the end of the intervention (day 10 of menstruation). Method of measurement: FSFI index.;Level of depression. Timepoint: At the beginning of the intervention , at the end of the intervention. Method of measurement: BDI questionnaire.;Quality of life. Timepoint: At the beginning of the intervention , at the end of the intervention. Method of measurement: SQOL-F questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Chakeri
Tabriz University of Medical Sciences
Outcome results
None listed